How are biological medicines different from “classical” medicines?
What is biosimilarity?
Is there any difference in safety between the biosimilar and the reference product?
What are the economic consequences of the use of biosimilars?
Are biosimilars safe?
The latest publication from the European Commission Directorate General for Industry replies of these and more questions related to biosimilars.
The document, entitled “What you Need to Know about Biosimilar Medicinal Products” is available on DG ENTR website in 5 languages: